CME: A Changing Approach to TNBC Management: Patients as Partners in Care

Media formats available:

Details

Presenters

Comments

Overview
Despite recent advances, triple-negative breast cancer (TNBC) remains difficult to treat due to a poor prognosis and a small number of effective treatments. Thus, clinicians’ priorities need to be aligned with patient goals and perspectives to ensure optimal care and overcome patient misunderstandings about treatment and clinical-trial options.
Join an expert panel of oncologists and oncology nurse practitioners for an in-depth discussion of patient-centered care practices for TNBC that incorporate and align with patient preferences for treatment. Panelists will also discuss effective strategies for TNBC management and the appropriate incorporation of novel therapies into treatment regimens.
Do you have patients who have been diagnosed with TNBC who could use education on treatment options, clinical trials, and available support resources? Direct your patients to MedLive.com to access the activity, “Navigating Treatment and Support for Triple-Negative Breast Cancer.”
Provider(s)/Educational Partner(s)
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC in collaboration with the National Breast Cancer Foundation (NBCF).
Acknowledgement
This activity has been supported by an independent educational grant from Gilead Sciences, Inc.
Date of Release/Expiration
This activity was released on July 18, 2023 and is valid until July 18, 2024. Requests for credit must be made no later than July 18, 2024.
Target Audience
The educational design of this activity addresses the needs of medical oncologists, pathologists, nurse practitioners, physician assistants, nurses, and other HCPs managing patients with triple-negative breast cancer (TNBC).
Learning Objectives
EDUCATIONAL OBJECTIVES
After participating in this educational activity, participants should be better able to:
- Describe current and emerging treatment approaches for TNBC, especially second-line treatments and strategies for advanced/metastatic TNBC
- Incorporate processes for addressing and aligning perspectives with patients throughout the care process for TNBC
- Discuss real-world data describing patient gaps, disparities, and perspectives regarding involvement in clinical trials
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

Faculty and Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Conflicts of Interest
Tiffany A. Traina, MD, FASCO Vice Chair, Department of Medicine Associate Attending Physician Breast Medicine Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medicine	Consultant, Advisor, Speaker: Agendia, AstraZeneca, Blueprint Medicines, bioTheranostics, Daiichi Sankyo, Ellipses Pharma, Fuji Pharma, G1 Therapeutics, GE Healthcare, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hengrui Pharmaceuticals, Infinity, Iteos Therapeutics, Merck, Novartis, Pfizer, SeaGen, TerSera Researcher: Astellas Pharma, AstraZeneca, Ayala Pharm, Carrick Pharma, Daiichi Sankyo, Genetech/Roche, Immunomedics, Innocrin Pharma, Pfizer
Gregory Vidal, MD, PhD Associate Professor University of Tennessee Health Science Center Director of Clinical Research West Cancer Center & Research Institute Chair, Breast Oncology Program, One Oncology	No relevant financial relationships to disclose
Stephanie Walker, RN MBC Thriver and Advocate Patient Advisor The BECOME Project	No relevant financial relationships to disclose

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/18/2023
Expiration Date: 07/18/2024

Presenters

Tiffany Traina, MD, FASCO

Guest

Gregory Vidal, MD, PhD

Guest

Stephanie Walker, RN

Guest

Facebook Comments

MinuteCE®
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
0.75 credits 7 episodes
- Allison Betof Warner, MD, PhD
- Hussein Tawbi, MD, PhD
0.75 credits 7 episodes
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
MinuteCE®
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
MinuteCE®
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Future Directions: Targeting LAG-3 in Melanoma Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
MinuteCE®
Future Directions: Targeting LAG-3 in Melanoma Treatment
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits